Mike Hollan

The company announced updates to its software to focus on this issue.

The CTO of Authenticx discusses preventing bias from becoming part of AI models.

The platform, named Pharmacy Match, will connect markets for specialty drugs.

Rademacher discusses his early work with trying to develop a vaccine for Ebola.

The Legend Biotech CEO discusses the results of the Phase 2 CARTITUDE-2 Cohort D study.

The platform will use machine-learning and generative AI to provide insurers with a variety of options and increase automation in their processes.

The CDMO’s facilities will be used to accelerate the production for a treatment of nAMD.

Health insurance executives say that digital technologies are getting members more involved in the healthcare system.

This is the first time in 20 years that CalPERS has changed its sole health plan provider.

The court ruled that the plaintiffs did not have standing to sue in this situation.

According to the company, the additional software makes it algorithm more accurate.

Craig Tooman, CEO of Silence Therapeutics, on steering through the rough biotech funding and investment waters post-pandemic—and how a retooled organizational approach has the company in a stronger position today in the growing field of gene silencing through siRNA drugs.

Leaders must address the root causes of negative public perception.

BioXcel’s VP of AI drug discovery discusses how use of the technology has advanced in the past year.

The device will be 4g-enabled and connect with the company’s remote monitoring platform.

The two companies are combining digital platforms to provide prescribers more options to monitor patients’ medication adherence.

Hypermedica and Ro announced platforms to help patients find access to affordable weight loss medications.

Both systems are over-the-counter products that provide continuous glucose monitoring.

Both partnerships will bring new research and healthcare opportunities to Abu Dhabi.

The partnership is described as the first of its kind.

The new agency will operate under the name Deerfield Group, and will also include Verge Scientific Communications.

The organization announced greater support for access and services for the community.

Anat Ashkenazi will leave the company at the end of July to pursue a career outside of pharma.

EVERSANA INTOUCH Media’s EVP discusses how the ban may impact the industry and how companies can prepare for it.

BD announced that it will pay cash to acquire the advanced monitoring solutions company.

Experts discuss the challenges that providers are facing when attempting to bring VBC to their members.

The Tarsus Pharmaceuticals CEO discusses the ways that his company is finding solutions that may have been overlooked.

The drug had previously been submitted, but required resubmission due to production issues.

The platforms are described as being first-in-category for the pharma industry.

Alkermes’ chief information officer discusses how he helped develop and build a welcoming workplace.